P-Glycoprotein Mediated Amyloid Clearance in Alzheimer's Disease

Alzheimer’s disease is characterised by the accumulation of amyloid-β (Aβ) peptides in the brain, a process that is counteracted under physiological conditions by active transport systems at the blood-brain barrier (BBB). P-glycoprotein (P-gp), a member of the ATP-binding cassette (ABC) transporter family, serves as a primary efflux pump for Aβ across the BBB endothelium. In Alzheimer’s disease, P-gp expression and transport activity are diminished through mechanisms such as proteasomal degradation and inflammatory signalling, leading to impaired clearance and progressive Aβ deposition. Restoration of P-gp function has thus emerged as a promising therapeutic strategy. Experimental approaches include proteasome inhibition to preserve P-gp levels, pharmacological induction of ABC transporter expression, and modulation of upstream regulatory pathways involving ubiquitin ligases and neuroinflammatory mediators. Together, these efforts seek to reinstate cerebral homeostasis by enhancing efflux clearance of pathogenic peptides and may contribute to slowing cognitive decline and neuropathological progression.

Research from Nature Portfolio

No recent Nature Portfolio content available.

P-Glycoprotein Mediated Amyloid Clearance in Alzheimer's Disease publication trend

The graph below shows the total number of articles in p-glycoprotein mediated amyloid clearance in alzheimer's disease across all publications each year (not limited to Nature Index journals).

Technical terms

P-glycoprotein (P-gp): An ATP-dependent efflux transporter (ABCB1) at the blood-brain barrier that exports amyloid-β peptides from the brain into the circulation.

Amyloid-β (Aβ): Peptides derived from amyloid precursor protein that accumulate in the brain and form plaques in Alzheimer’s disease.

Blood-brain barrier (BBB): A specialised endothelial interface that regulates molecular exchange between the blood and central nervous system.

ATP-binding cassette (ABC) transporters: A superfamily of membrane proteins that use ATP hydrolysis to translocate substrates, including neurotoxic peptides, across cellular barriers.

Proteasome: A multi-enzyme complex responsible for degradation of ubiquitinated proteins, whose activity can regulate P-gp turnover at the blood-brain barrier.

References

1. Proteasome inhibition protects blood–brain barrier P-glycoprotein and lowers Aβ brain levels in an Alzheimer’s disease model. Fluids and Barriers of the CNS (2023).
2. Emerging Role of ABC Transporters in Glia Cells in Health and Diseases of the Central Nervous System. Cells (2024).
3. Enhancing of cerebral Abeta clearance by modulation of ABC transporter expression: a review of experimental approaches. Frontiers in Aging Neuroscience (2024).